# Exploring the therapeutic potential of phytochemicals apigenin and ellagic acid in managing polycystic ovarian syndrome and its comorbidities: a comprehensive review

## TL;DR

This review explores how apigenin and ellagic acid, two plant-based compounds, may help manage PCOS by improving insulin sensitivity and reducing inflammation.

## Contribution

The paper provides a comprehensive review of apigenin and ellagic acid's mechanisms and potential as natural therapies for PCOS and its comorbidities.

## Key findings

- Apigenin and ellagic acid show anti-inflammatory, antioxidant, and insulin-sensitizing properties relevant to PCOS.
- These compounds regulate ovarian steroidogenesis and reduce hyperandrogenism via 5α-reductase inhibition.
- Nano-delivery systems may improve the bioavailability and clinical applicability of apigenin and ellagic acid.

## Abstract

Polycystic Ovarian Syndrome (PCOS) is a complex endocrine and metabolic disorder affecting women of reproductive age, characterized by hyperandrogenism, insulin resistance, chronic inflammation, and ovulatory dysfunction. Conventional therapies, such as oral contraceptives, insulin sensitizers, and anti-androgens, primarily offer symptomatic relief and are often associated with chronic adverse effects, underscoring the need for safer and more holistic alternatives. Naturally occurring bioactives have emerged as promising adjunct or alternative therapeutic agents in this context. This review critically examines the therapeutic potential of two phytochemicals or natural bioactives, apigenin and ellagic acid, in the integrative management of PCOS and its associated metabolic disturbances and comorbidities. Apigenin, a flavonoid abundantly present in parsley, chamomile, and citrus fruits, and ellagic acid, a polyphenol found in pomegranates and berries, both demonstrate significant anti-inflammatory, antioxidant, insulin-sensitizing, and anti-androgenic activities. Mechanistic studies reveal their ability to regulate ovarian steroidogenesis, suppress pro-inflammatory cytokines, improve insulin sensitivity via the PI3K/Akt signaling pathway, and reduce hyperandrogenism by inhibiting 5α-reductase. Preclinical and preliminary clinical studies support the efficacy of these treatments in restoring ovarian morphology, normalizing hormonal profiles, and ameliorating metabolic dysfunctions in PCOS models. Although limited by poor bioavailability, both compounds exhibit favorable safety and metabolic profiles, and emerging formulation approaches such as nano-delivery systems, phytosomes, and liposomes offer promising strategies to enhance their clinical applicability. This review advocates incorporating apigenin and ellagic acid into integrative PCOS treatment strategies. It highlights the need for well-designed clinical trials to validate efficacy, establish standardized dosing, and develop advanced delivery systems.

This graphical abstract represents an overview of PCOS pathology and the therapeutic potential of natural compounds apigenin and ellagic acid, highlighting their effects on androgen levels, insulin sensitivity, oxidative stress, and inflammation, with associated clinical and pre-clinical outcomes.

Illustration outlining Polycystic Ovary Syndrome (PCOS). A woman holds a symbol of female reproductive organs. Symptoms listed include hyperandrogenism, insulin resistance, oxidative stress, and chronic inflammation. Natural therapeutics such as apigenin and ellagic acid are shown. Clinical outcomes include restored cyst formation, improved insulin sensitivity, and reduced metabolic risk. Pre-clinical outcomes list restored ovarian morphology and similar benefits.